Solifenacin
Vesicare
- Dosage form
- Tablet
- Available strengths
- 5 mg, 10 mg
- Drug class
- Antimuscarinic (anticholinergic) urinary antispasmodic
- Common brand
- Vesicare
Clinical overview. Solifenacin (Vesicare) is an antimuscarinic medication used to treat overactive bladder in adults, reducing urinary urgency, frequency, and urge incontinence. It is taken once daily and can be taken with or without food. Common side effects include dry mouth, constipation, and blurred vision, while serious but rare risks include angioedema, severe constipation, urinary retention, and heart rhythm changes.
Indication
Common therapeutic uses
- Solifenacin (Vesicare) is used to treat overactive bladder in adults, including symptoms of urgency, frequent urination, and urge urinary incontinence.
Pregnancy
Risk assessment and monitoring considerations
- There is no adequate data on the use of solifenacin in pregnant women; it should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.
- Women of childbearing potential should use adequate contraception while being considered for treatment.
Breastfeeding
Infant exposure considerations
- It is not known whether solifenacin passes into human breast milk.
- Because many drugs do pass into breast milk, solifenacin should not be used while breastfeeding; a decision should be made to either stop breastfeeding or stop the medication.
Geriatrics
Dosing and tolerability considerations
- Solifenacin has shown similar safety and effectiveness in older adults 65 years and older compared with younger patients in clinical studies.
- Blood levels of solifenacin are somewhat higher in older adults, so caution is warranted, particularly in those with reduced kidney or liver function.
Pediatrics
Use in children and adolescents
- Safety and effectiveness of solifenacin have not been established in children, so it is not indicated for pediatric use.
Dosage & Administration
Practical dosing and administration
- The recommended starting dose of Vesicare is 5 mg once daily.
- If the 5 mg dose is well tolerated, the dose may be increased to 10 mg once daily.
- The maximum effect on bladder symptoms can take up to 4 weeks to become apparent.
- For patients with severe kidney impairment, or moderate liver impairment, the dose should not exceed 5 mg daily; Vesicare is not recommended for patients with severe liver impairment.
- When used with a strong CYP3A4 inhibitor such as ketoconazole, the dose should be limited to 5 mg daily.
- Vesicare should be swallowed whole with liquid; it can be taken with or without food.
- If a dose is missed, the next tablet should be taken as scheduled; doses should not be doubled.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Overdose with solifenacin can cause severe anticholinergic effects, including fixed and dilated pupils, blurred vision, tremor, dry skin, and problems with balance and coordination.
- The highest known accidental overdose caused mental status changes that resolved after treatment with activated charcoal.
- Symptoms from repeated high daily doses have resolved within about a week after stopping the drug.
- Treatment of overdose includes gastric lavage, supportive care, and ECG (heart rhythm) monitoring.
Common side effects
Frequently reported tolerability concerns
- Dry mouth may occur, and is more common at the higher dose.
- Constipation may occur.
- Blurred vision may occur.
- Nausea may occur.
- Indigestion (dyspepsia) may occur.
- Upper abdominal pain may occur.
- Dry eyes may occur.
- Fatigue may occur.
- Swelling of the lower legs may occur.
- Urinary tract infection symptoms may occur.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Angioedema, meaning swelling of the face, lips, tongue, or throat, has been reported, sometimes after the very first dose, and can be life-threatening if it affects the airway.
- Anaphylactic (severe allergic) reactions have been reported.
- Severe constipation, including fecal impaction or bowel obstruction, has occurred rarely, especially at the 10 mg dose.
- Urinary retention, meaning inability to empty the bladder, may occur, particularly in patients with bladder outflow obstruction.
- QT interval prolongation and Torsade de Pointes, a dangerous heart rhythm, have been reported, particularly at higher doses or in patients with existing risk factors.
- Severe skin reactions, including exfoliative dermatitis and erythema multiforme, have been reported.
- Reduced ability to sweat can lead to heat prostration in hot conditions or with strenuous activity.
- Confusion, disorientation, delirium, and hallucinations have been reported, particularly in older adults.
- Liver function test abnormalities have been reported.
- Seek urgent medical attention for swelling of the face, lips, tongue, or throat, difficulty breathing, severe abdominal pain, or an inability to urinate.
Use with caution
Situations requiring closer assessment
- Use with caution in patients with reduced ability to sweat, due to the risk of overheating in hot weather or during exercise.
- Use with caution in patients with bladder outflow obstruction, due to the risk of urinary retention.
- Use with caution in patients with reduced gastrointestinal motility.
- Use with caution in patients with reduced liver or kidney function, with dose limits as described above.
- Use with caution in patients with a history of QT prolongation, electrolyte disturbances, or who take other medications that can affect heart rhythm.
- Use with caution in patients with pre-existing heart disease.
- Use with caution when driving or operating machinery, since blurred vision and drowsiness can occur.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients with urinary retention.
- Contraindicated in patients who are dependent on dialysis.
- Contraindicated in patients with gastroparesis (delayed stomach emptying).
- Contraindicated in patients with uncontrolled narrow-angle glaucoma.
- Contraindicated in patients with known hypersensitivity to solifenacin or any ingredient in the formulation.
Drug interactions
Clinically relevant combinations
- Other medications with anticholinergic effects can add to solifenacin's effects and side effects, such as dry mouth, constipation, and blurred vision.
- Cholinergic drugs may have reduced effect when combined with solifenacin, since solifenacin works against this system.
- Solifenacin may reduce the effectiveness of drugs that stimulate gut motility, such as metoclopramide.
- Strong CYP3A4 inhibitors, such as ketoconazole, clarithromycin, and erythromycin, can significantly raise solifenacin blood levels, requiring a dose limit of 5 mg daily.
- No significant interaction has been found between solifenacin and digoxin, oral contraceptives, or warfarin.
Food interactions
Meal-related administration
- Vesicare can be taken with or without food; there is no significant effect of food on how the medicine is absorbed.
- Grapefruit juice may increase solifenacin blood levels and should be used with caution.
Time of administration
Practical scheduling
- Vesicare is taken once daily, at about the same time each day, and can be taken with or without food.
- It may take up to 4 weeks of regular use to see the full benefit for bladder symptoms.
Storage
Product handling
- Store Vesicare tablets between 15°C and 30°C.
Patient take-away
Key counselling points for a quick closing summary
- Vesicare (solifenacin) is taken once daily to help reduce bladder urgency, frequency, and leakage from an overactive bladder.
- Dry mouth and constipation are the most common side effects; staying hydrated and eating enough fibre can help.
- Because this medicine can reduce sweating, take care to avoid overheating in hot weather or during exercise.
- Seek urgent medical care for swelling of the face or throat, difficulty breathing, or an inability to urinate.
- It can take up to 4 weeks of regular use to notice the full benefit.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.